Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01930786 · ClinicalTrials.gov registry record
An Adult Spasticity Registry of OnabotulinumtoxinA Treatment
A clinical trial, sponsored by Allergan.
- Completed
- Registry status
- 744
- Enrollment target
NCT01930786: Completed study, sponsored by Allergan.
NCT01930786 is a clinical trial that has completed, run by Allergan. The registered enrollment target is 744 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01930786 has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- 744 participants
- Enrollment target
Study Summary
This is a registry study in adults with spasticity to determine onabotulinumtoxinA use in clinical practice. Treatment will be administered in accordance with physician standard practice. All treatment decisions lie with the physician.
Interventions
- DRUG onabotulinumtoxinA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 744 participants |
| Start Date | 2013-10-16 |
| Est. Completion | 2017-10-09 |
What the finished NCT01930786 record still lists
NCT01930786 is an observational study that tracks outcomes without assigning an intervention. The registered 744 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which onabotulinumtoxinA is the first listed.
NCT01930786 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01930786 about?
NCT01930786 is a clinical study titled "An Adult Spasticity Registry of OnabotulinumtoxinA Treatment". This is a registry study in adults with spasticity to determine onabotulinumtoxinA use in clinical practice. Treatment will be administered in accordance with physician standard practice. All treatment decisions lie with the physician.
What is the current status of trial NCT01930786?
This trial is currently completed. The enrollment target is 744 participants. The study started on 2013-10-16. Estimated completion is 2017-10-09.
What interventions are being tested in trial NCT01930786?
The interventions under investigation include: onabotulinumtoxinA (DRUG).
Who is sponsoring clinical trial NCT01930786?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05619185 · 744 participants · NA
A SMART Evaluation of an Adaptive Web-based AUD Treatment for Service Members and Their Partners
- NCT06417814 · 744 participants · Phase 3
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- NCT07046351 · 744 participants · NA
weSIPsmarter: Evaluating a Digital Health Intervention Aimed at Reducing Sugary Drinks Among Rural Head Start Preschoolers and Their Parents
- NCT07199569 · 744 participants · Phase 2
Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI